PLoS ONE (Oct 2010)

Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.

  • Toru Hiratsuka,
  • Shinsuke Matsuzaki,
  • Shingo Miyata,
  • Mitsuhiro Kinoshita,
  • Kazuaki Kakehi,
  • Shinji Nishida,
  • Taiichi Katayama,
  • Masaya Tohyama

DOI
https://doi.org/10.1371/journal.pone.0013280
Journal volume & issue
Vol. 5, no. 10
p. e13280

Abstract

Read online

BackgroundRecently, several studies have reported Yokukansan (Tsumura TJ-54), a traditional Japanese medicine, as a potential new drug for the treatment of Alzheimer's disease (AD). Endoplasmic reticulum (ER) stress is known to play an important role in the pathogenesis of AD, particularly in neuronal death. Therefore, we examined the effect of Yokukansan on ER stress-induced neurotoxicity and on familial AD-linked presenilin-1 mutation-associated cell death.MethodsWe employed the WST-1 assay and monitored morphological changes to evaluate cell viability following Yokukansan treatment or treatment with its components. Western blotting and PCR were used to observe the expression levels of GRP78/BiP, caspase-4 and C/EBP homologous protein.ResultsYokukansan inhibited neuronal death during ER stress, with Cnidii Rhizoma (Senkyu), a component of Yokukansan, being particularly effective. We also showed that Yokukansan and Senkyu affect the unfolded protein response following ER stress and that these drugs inhibit the activation of caspase-4, resulting in the inhibition of ER stress-induced neuronal death. Furthermore, we found that the protective effect of Yokukansan and Senkyu against ER stress could be attributed to the ferulic acid content of these two drugs.ConclusionsOur results indicate that Yokukansan, Senkyu and ferulic acid are protective against ER stress-induced neuronal cell death and may provide a possible new treatment for AD.